Abdulgabar Salama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdulgabar Salama has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Holger Kiesewetter
Medicover, Haemostaseologicum Mitte
17 shared publicationsBeate Mayer
Institute of Transfusion Medicine, Charité Unversitätsmedizin Berlin, Berlin, Germany
13 shared publicationsH. Kiesewetter
Charité—Universitätsmedizin Berlin
10 shared publicationsOliver Meyer
Charite, Inst Transfus Medi, D-13353 Berlin, Germany
10 shared publicationsO. Meyer
Institut für Transfusionsmedizin, Charité– Universitätsmedizin Berlin, Berlin, Germany
7 shared publicationsSalih Yürek
Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
6 shared publications
Latest Publications
- Open Access
- 29 November 2022
- Published by Wiley
Polyclonal Anti-D Antibodies Significantly Reduce the Rate of Miscarriages in Rh(D) positive Women with Recurrent Pregnancy loss
Objective: Coating of autologous red blood cells (RBCs) with polyclonal antibodies to Rh(D) antigen may result in an immunomodulation and improved outcome in Rh(D) positive women with recurrent pregnancy loss (RPL). Design: Retrospective data analysis. Setting: Rh(D) positive women with a history of RPL and ineffective treatment with low molecular weight heparin (LMWH) and/or aspirin Methods: Anti-D (300 µg) was given subcutaneously to 60 women either prior to pregnancy and/or two times within 12 weeks of gestation. Main outcome measures: Births of healthy child/children. Results: Treatment with Anti-D resulted in successful pregnancies in 67% of all cases. The remaining women had only aborts (23%) or did not become pregnant (10%). None of the treated women has developed anaemia due to this treatment or any other significant adverse reaction. The rate of successful pregnancies does not appear to be influenced by the administration of: Anti-D prior to pregnancy, age, thrombophilia or previous alive births. Conclusion: The improved outcome following the administration of Anti-D in women with RPL might be explained by immune modulations induced by different immune reactions including polarization of decidual macrophages. The results obtained in this study clearly indicate that Anti-D is safe and highly effective in treatment of Rh(D) positive women with RPL. However, further studies are required to support our results and to find out the optimal dose and timing of Anti-D administration. Funding: There was no funding included. Key words: abort, Anti-D, aspirin, low molecular weight heparin, new treatment, recurrent pregnancy loss
- 29 November 2022
- Published by Wiley
Open AccessPolyclonal Anti-D Antibodies Significantly Reduce the Rate of Miscarriages in Rh(D) positive Women with Recurrent Pregnancy loss
Objective: Coating of autologous red blood cells (RBCs) with polyclonal antibodies to Rh(D) antigen may result in an immunomodulation and improved outcome in Rh(D) positive women with recurrent pregnancy loss (RPL). Design: Retrospective data analysis. Setting: Rh(D) positive women with a history of RPL and ineffective treatment with low molecular weight heparin (LMWH) and/or aspirin Methods: Anti-D (300 µg) was given subcutaneously to 60 women either prior to pregnancy and/or two times within 12 weeks of gestation. Main outcome measures: Births of healthy child/children. Results: Treatment with Anti-D resulted in successful pregnancies in 67% of all cases. The remaining women had only aborts (23%) or did not become pregnant (10%). None of the treated women has developed anaemia due to this treatment or any other significant adverse reaction. The rate of successful pregnancies does not appear to be influenced by the administration of: Anti-D prior to pregnancy, age, thrombophilia or previous alive births. Conclusion: The improved outcome following the administration of Anti-D in women with RPL might be explained by immune modulations induced by different immune reactions including polarization of decidual macrophages. The results obtained in this study clearly indicate that Anti-D is safe and highly effective in treatment of Rh(D) positive women with RPL. However, further studies are required to support our results and to find out the optimal dose and timing of Anti-D administration. Funding: There was no funding included. Key words: abort, Anti-D, aspirin, low molecular weight heparin, new treatment, recurrent pregnancy loss
- Open Access
- 27 January 2019
- Published by Wiley in Transfusion Medicine
- Vol. 29 (1) , 48-54
Efficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia
Summary: Objectives: To assess the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (Panzyga®), a novel human normal IVIG 10%, in patients with chronic immune thrombocytopenia (ITP).Background: First‐line treatment options in ITP include IVIGs.Methods: In this prospective, open‐label, non‐controlled, multicentre, phase III study, patients received a daily dose of IVIG 10% (1 g kg−1 body weight) for two consecutive days. The primary end point was clinical response rate; secondary end points included alternate response definitions, time to response, response duration, platelet counts, regression of bleeding and safety.Results: Forty patients were enrolled (57·5% male, mean age 36·7 years); the full analysis set comprised 36 patients. A clinical response was seen for 29 of 36 patients (80·6%). Median time to response and response duration was 2 days and 14 days, respectively. IVIG 10% was well tolerated at a maximum infusion rate of 8 mg (kg min)−1 in all but one patient; adverse events were mainly mild to moderate in severity, and the most frequent was headache (42·5%).Conclusion: IVIG 10% is well tolerated even at a high infusion speed and induces a rapid platelet count increase, thus decreasing the bleeding rate and the severity of bleeding events.Trial registry: ClinicalTrials.gov record: NCT01349790.
- 27 January 2019
- Published by Wiley in Transfusion Medicine
- Vol. 29 (1) , 48-54
Open AccessEfficacy and safety of a new intravenous immunoglobulin (Panzyga®) in chronic immune thrombocytopenia
Summary: Objectives: To assess the efficacy and safety of intravenous immunoglobulin (IVIG) 10% (Panzyga®), a novel human normal IVIG 10%, in patients with chronic immune thrombocytopenia (ITP).Background: First‐line treatment options in ITP include IVIGs.Methods: In this prospective, open‐label, non‐controlled, multicentre, phase III study, patients received a daily dose of IVIG 10% (1 g kg−1 body weight) for two consecutive days. The primary end point was clinical response rate; secondary end points included alternate response definitions, time to response, response duration, platelet counts, regression of bleeding and safety.Results: Forty patients were enrolled (57·5% male, mean age 36·7 years); the full analysis set comprised 36 patients. A clinical response was seen for 29 of 36 patients (80·6%). Median time to response and response duration was 2 days and 14 days, respectively. IVIG 10% was well tolerated at a maximum infusion rate of 8 mg (kg min)−1 in all but one patient; adverse events were mainly mild to moderate in severity, and the most frequent was headache (42·5%).Conclusion: IVIG 10% is well tolerated even at a high infusion speed and induces a rapid platelet count increase, thus decreasing the bleeding rate and the severity of bleeding events.Trial registry: ClinicalTrials.gov record: NCT01349790.
- Open Access
- 1 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198184
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice
Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and tolerability of the drugs used in practice. We retrospectively reviewed the results of therapy of 400 patients with chronic ITP. All Patients were treated at our institution between 1996–2016 under consideration of guidelines, general recommendations, and individual aspects, including gender, age, weight, comorbidity, patient’s medical history and bleeding risk. Treatment was not required in 25% of patients (n = 100) during observation. In treated patients (n = 300), the rate of patients that responded and tolerated treatment with prednisolone was 59% (52/88), with azathioprine 32% (29/90), with eltrombopag 49% (31/63), with romiplostim 59% 27/45, with IVIG (intravenous immunoglobulines) 75% (94/126), with anti-D 37% (19/52) and with dexamethasone 60% (25/42) patients. Eighteen treated patients (6%) entered sustained remission after treatment with various drugs. Twenty-six patients underwent splenectomy (Splx) resulting in sustained remission in 15 cases (60%). Only two patients remained refractory to Splx and to all used drugs. None of the currently available drugs used in the treatment of ITP are invariably safe and effective. Responses, the duration of response, intolerability, and the course of disease are unpredictable. Although the treatment of ITP has considerably improved in the recent years, the currently available drugs may rarely cure affected patients. The need for safe and effective therapy in ITP is evident. Optimal treatment decisions for each patient remains a challenge in many cases.
- 1 June 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198184
Open AccessEfficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice
Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and tolerability of the drugs used in practice. We retrospectively reviewed the results of therapy of 400 patients with chronic ITP. All Patients were treated at our institution between 1996–2016 under consideration of guidelines, general recommendations, and individual aspects, including gender, age, weight, comorbidity, patient’s medical history and bleeding risk. Treatment was not required in 25% of patients (n = 100) during observation. In treated patients (n = 300), the rate of patients that responded and tolerated treatment with prednisolone was 59% (52/88), with azathioprine 32% (29/90), with eltrombopag 49% (31/63), with romiplostim 59% 27/45, with IVIG (intravenous immunoglobulines) 75% (94/126), with anti-D 37% (19/52) and with dexamethasone 60% (25/42) patients. Eighteen treated patients (6%) entered sustained remission after treatment with various drugs. Twenty-six patients underwent splenectomy (Splx) resulting in sustained remission in 15 cases (60%). Only two patients remained refractory to Splx and to all used drugs. None of the currently available drugs used in the treatment of ITP are invariably safe and effective. Responses, the duration of response, intolerability, and the course of disease are unpredictable. Although the treatment of ITP has considerably improved in the recent years, the currently available drugs may rarely cure affected patients. The need for safe and effective therapy in ITP is evident. Optimal treatment decisions for each patient remains a challenge in many cases.
- 1 January 2018
- Vol. 16 (3) , 307-312
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review
Background. There is evidence that the thrombopoietin-receptor agonists romiplostim and eltrombopag may have different therapeutic values and adverse reaction profiles. Here we present new data and provide a review of all studies dealing with switching between these two drugs. Materials and methods. A total of 89 patients (38 males and 51 females, aged between 14-87 years) were treated with eltrombopag and/or romiplostim between 2007 and 2016 at our institution. Eltrombopag was switched to romiplostim or vice versa in 32 patients. In addition, all published data concerning patients treated sequentially with different thrombopoietin-receptor agonists were identified via a computer-assisted search and summarised in this article. Results. Thirty-two of 89 patients treated with a thrombopoietin-receptor agonist in our institution were given both eltrombopag and romiplostim sequentially. Therapy was switched to the alternate thrombopoietin-receptor agonist 36 times, due to inefficacy (n=21), adverse reactions (n=14), and a patient's preference (n=1). In addition, data from 126 patients who have been treated with both agonists have been published by other groups. In total eltrombopag was replaced by romiplostim in 56 cases due to poor or no response or to adverse reactions. Forty-five patients responded to treatment with romiplostim, 11 patients shared cross-resistance and nine had adverse reactions to romiplostim. In contrast, romiplostim was replaced by eltrombopag in 106 cases. Seventy-eight patients responded to eltrombopag, 27 shared cross-resistance and 19 had adverse reactions to eltrombopag. Discussion. Eltrombopag and romiplostim often share bidirectional cross-resistance and/or adverse reactions. Both drugs appear to cause more adverse reactions than have been previously reported.
- 1 January 2018
- Vol. 16 (3) , 307-312
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review
Background. There is evidence that the thrombopoietin-receptor agonists romiplostim and eltrombopag may have different therapeutic values and adverse reaction profiles. Here we present new data and provide a review of all studies dealing with switching between these two drugs. Materials and methods. A total of 89 patients (38 males and 51 females, aged between 14-87 years) were treated with eltrombopag and/or romiplostim between 2007 and 2016 at our institution. Eltrombopag was switched to romiplostim or vice versa in 32 patients. In addition, all published data concerning patients treated sequentially with different thrombopoietin-receptor agonists were identified via a computer-assisted search and summarised in this article. Results. Thirty-two of 89 patients treated with a thrombopoietin-receptor agonist in our institution were given both eltrombopag and romiplostim sequentially. Therapy was switched to the alternate thrombopoietin-receptor agonist 36 times, due to inefficacy (n=21), adverse reactions (n=14), and a patient's preference (n=1). In addition, data from 126 patients who have been treated with both agonists have been published by other groups. In total eltrombopag was replaced by romiplostim in 56 cases due to poor or no response or to adverse reactions. Forty-five patients responded to treatment with romiplostim, 11 patients shared cross-resistance and nine had adverse reactions to romiplostim. In contrast, romiplostim was replaced by eltrombopag in 106 cases. Seventy-eight patients responded to eltrombopag, 27 shared cross-resistance and 19 had adverse reactions to eltrombopag. Discussion. Eltrombopag and romiplostim often share bidirectional cross-resistance and/or adverse reactions. Both drugs appear to cause more adverse reactions than have been previously reported.
- Open Access
- 1 January 2018
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 7 (3) , 87-95
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
- 1 January 2018
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 7 (3) , 87-95
Open AccessEfficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
- Open Access
- 27 September 2017
- Published by Wiley in European Journal of Haematology
- Vol. 100 (1) , 36-44
Eryptosis in autoimmune haemolytic anaemia
Objective: Haemolysis and anaemia related to autoimmune haemolytic anaemia (AIHA) of warm type (wAIHA) and of cold type (cAIHA) are believed to be solely due to antibody and/or complement‐mediated destruction and clearance of red blood cells (RBCs). There is evidence that RBCs of affected patients may also undergo eryptosis, the suicidal death of RBCs.Method: RBCs from 24 patients with wAIHA, 7 patients with chronic cAIHA and one patient with AIHA of mixed type were analysed for exposed phosphatidylserine (PS) by treatment with phycoerythrin‐labelled Annexin V, and cell‐associated fluorescence was measured using a MACSQuant flow cytometer.Results: PS‐exposing RBCs were detected in 7 of 13 patients with clinically significant wAIHA. Haemolysis was mostly related to IgM or IgA autoantibodies (aab) in those patients. In contrast, PS exposure in 11 patients with wAIHA in complete remission was comparable to that in healthy blood donors. All patients with chronic cAIHA and the patient with AIHA of mixed type showed haemolytic activity and high numbers of PS‐exposing RBCs. Patients with decompensated AIHA appear to respond to treatment with erythropoietin, which is a known inhibitor of eryptosis.Conclusion: Eryptosis may frequently occur in AIHA related to IgM or IgA aab. Inhibition of eryptosis with erythropoietin may represent a new therapeutic option in the treatment of AIHA.
- 27 September 2017
- Published by Wiley in European Journal of Haematology
- Vol. 100 (1) , 36-44
Open AccessEryptosis in autoimmune haemolytic anaemia
Objective: Haemolysis and anaemia related to autoimmune haemolytic anaemia (AIHA) of warm type (wAIHA) and of cold type (cAIHA) are believed to be solely due to antibody and/or complement‐mediated destruction and clearance of red blood cells (RBCs). There is evidence that RBCs of affected patients may also undergo eryptosis, the suicidal death of RBCs.Method: RBCs from 24 patients with wAIHA, 7 patients with chronic cAIHA and one patient with AIHA of mixed type were analysed for exposed phosphatidylserine (PS) by treatment with phycoerythrin‐labelled Annexin V, and cell‐associated fluorescence was measured using a MACSQuant flow cytometer.Results: PS‐exposing RBCs were detected in 7 of 13 patients with clinically significant wAIHA. Haemolysis was mostly related to IgM or IgA autoantibodies (aab) in those patients. In contrast, PS exposure in 11 patients with wAIHA in complete remission was comparable to that in healthy blood donors. All patients with chronic cAIHA and the patient with AIHA of mixed type showed haemolytic activity and high numbers of PS‐exposing RBCs. Patients with decompensated AIHA appear to respond to treatment with erythropoietin, which is a known inhibitor of eryptosis.Conclusion: Eryptosis may frequently occur in AIHA related to IgM or IgA aab. Inhibition of eryptosis with erythropoietin may represent a new therapeutic option in the treatment of AIHA.
- 26 September 2017
- Published by Wiley in Vox Sanguinis
- Vol. 112 (8) , 767-772
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia
Background and Objectives: The clinical significance of immune thrombocytopenia (ITP) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy. Tranexamic acid (TA) is increasingly used in preventing and reducing bleeding in several medical settings. There is little information on whether TA may also be useful in the management of ITP.Materials and Methods: Twelve patients with ITP were treated with TA (0·5–3 g/day) due to recognizable bleeding. Ten of the 12 patients were under regular treatment for ITP. The remaining two patients did not require additional therapy.Results: Cessation or, at least, significant improvement of bleeding was achieved shortly after the initiation of TA in all cases. TA was well tolerated and discontinued after cessation of bleeding.Conclusions: We recommend the use of TA in ITP patients with bleeding and/or an increased bleeding risk. Ultimately, cessation of bleeding plays a key role in the management of such affected patients. However, future studies are required to optimize dose and administration routes (intravenous or oral).
- 26 September 2017
- Published by Wiley in Vox Sanguinis
- Vol. 112 (8) , 767-772
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia
Background and Objectives: The clinical significance of immune thrombocytopenia (ITP) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy. Tranexamic acid (TA) is increasingly used in preventing and reducing bleeding in several medical settings. There is little information on whether TA may also be useful in the management of ITP.Materials and Methods: Twelve patients with ITP were treated with TA (0·5–3 g/day) due to recognizable bleeding. Ten of the 12 patients were under regular treatment for ITP. The remaining two patients did not require additional therapy.Results: Cessation or, at least, significant improvement of bleeding was achieved shortly after the initiation of TA in all cases. TA was well tolerated and discontinued after cessation of bleeding.Conclusions: We recommend the use of TA in ITP patients with bleeding and/or an increased bleeding risk. Ultimately, cessation of bleeding plays a key role in the management of such affected patients. However, future studies are required to optimize dose and administration routes (intravenous or oral).
- 30 May 2017
- Published by Georg Thieme Verlag KG in Transfusionsmedizin
- Vol. 7 (02) , 104-119
Autoimmunhämolytische Anämien: Diagnose und Therapie
Autoimmunhämolytische Anämien entstehen durch die Bildung von Wärme- und bzw. oder Kälteautoantikörpern, die an Oberflächenantigene von Erythrozyten binden. Die mit Antikörpern sensibilisierten Erythrozyten können phagozytiert oder durch vollständige Komplementaktivierung intravasal zerstört werden. Neben der serologischen Untersuchung zur Bestätigung der Diagnose muss ebenfalls nach der zugrunde liegenden Ursache geforscht werden, um die Therapie zu optimieren.
- 30 May 2017
- Published by Georg Thieme Verlag KG in Transfusionsmedizin
- Vol. 7 (02) , 104-119
Autoimmunhämolytische Anämien: Diagnose und Therapie
Autoimmunhämolytische Anämien entstehen durch die Bildung von Wärme- und bzw. oder Kälteautoantikörpern, die an Oberflächenantigene von Erythrozyten binden. Die mit Antikörpern sensibilisierten Erythrozyten können phagozytiert oder durch vollständige Komplementaktivierung intravasal zerstört werden. Neben der serologischen Untersuchung zur Bestätigung der Diagnose muss ebenfalls nach der zugrunde liegenden Ursache geforscht werden, um die Therapie zu optimieren.
- Open Access
- 30 December 2016
- Published by Springer Nature in BMC Veterinary Research
- Vol. 12 (1) , 290
Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
- 30 December 2016
- Published by Springer Nature in BMC Veterinary Research
- Vol. 12 (1) , 290
Open AccessErratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
- 22 December 2016
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 22 (1) , 27-38
Emerging drugs for immune thrombocytopenia (ITP)
Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have significant bleeding risks due to low platelet counts and require treatment. The etiology of ITP is an immunological labyrinth. Currently available treatment options are usually not only nonspecific, but are also associated with some risks. Areas covered: Several useful drugs for the treatment of ITP are currently available. Furthermore, ongoing trials with new drugs and preclinical development of additional drugs may help to improve and determine their value. Expert opinion: ITP is a heterogeneous complex requiring individualized treatment. None of the available drugs are specific, nor are they invariably safe and effective. Thus, the need for specific therapy is evident.
- 22 December 2016
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 22 (1) , 27-38
Emerging drugs for immune thrombocytopenia (ITP)
Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have significant bleeding risks due to low platelet counts and require treatment. The etiology of ITP is an immunological labyrinth. Currently available treatment options are usually not only nonspecific, but are also associated with some risks. Areas covered: Several useful drugs for the treatment of ITP are currently available. Furthermore, ongoing trials with new drugs and preclinical development of additional drugs may help to improve and determine their value. Expert opinion: ITP is a heterogeneous complex requiring individualized treatment. None of the available drugs are specific, nor are they invariably safe and effective. Thus, the need for specific therapy is evident.